MRNA is trading at $57.44 (+5.68%) on continued momentum following positive clinical data for its flu and hantavirus vaccine candidates.
- The stock has rallied approximately 24% since May 5, significantly outperforming the S&P 500, which rose just 0.17% in the same timeframe.
- Pre-market gains were fueled by reports of a hantavirus vaccine response to a cruise ship outbreak, extending a rally that included a 12% jump on May 8.
- Moderna's upward trajectory persists despite broader market headwinds and geopolitical caution surrounding U.S.-Iran tensions.